DOI: 10.12890/2025_005203
Complete response after avelumab maintenance therapy: successful management of metastatic urothelial carcinoma
Authors
ritapinho15@gmail.com
Keywords
Avelumab, metastatic urothelial carcinoma, maintenance therapy, complete responseAbstract
Urothelial carcinoma is one of the most frequently diagnosed cancer types in the world and despite progress in treatment, it remains a lethal disease in the metastatic stage. Because of its high programmed cell death ligand 1 protein expression, it is associated with an increased response to immune checkpoints inhibitors. In the past few years, the gold standard for first-line treatment of metastatic urothelial carcinoma has been platinum-based chemotherapy, and avelumab (PD-1 inhibitor) maintenance therapy for non-progressing tumours. After the remarkable benefit demonstrated in the EV-302 study, the guidelines were recently revised to include enfortumab vedotin plus pembrolizumab as the new standard of care in this setting.
Despite the new recommendations, in some countries, this combination is still pending approval. Furthermore, for patients who are ineligible for enfortumab vedotin plus pembrolizumab, platinum-based chemotherapy followed by avelumab maintenance therapy continues to be a preferred treatment option.
This report presents a woman diagnosed with metastatic urothelial carcinoma with histologically confirmed complete response after cisplatin and gemcitabine chemotherapy and avelumab as maintenance therapy, which has been reported in only a few cases in the literature.
References
- International Agency for Research on Cancer. Estimated number of new cases in 2022, worldwide, both sexes, all ages. Access date November 2024. https://gco.iarc.fr/today/en/fact-sheets-cancers.
- Liu S, Yang T, Na R, Hu M, Zhang L, Fu Y, et al. The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. Int Urol Nephrol 2015;47:951-958.
- Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowen NC, Efstathiou JA, et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol 2022;81:95–103.
- Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:244–258.
- Powels T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 2024;35:485–490.
- Powles T, Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-censits J, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol 2023;34:S1340.
- Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Curr Opin Oncol 2015;27:191-200.
- Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Eng J Med 2020;383:1218-1230.
- Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullén A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: Results from the Javelin Bladder 100 Trial after 2 years of follow-up. J Clin Oncology 2023;41:3486-3492.
- Mansinho A, Cruz A, Marconi L, Pinto C, Augusto I. Avelumab as first-line maintenance treatment in locally advanced or metastatic urothelial carcinoma. Adv Ther 2023;40:4134-4150.
